UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of report (Date of earliest event reported):
(Exact name of Registrant as Specified in its Charter)
| (State
or other jurisdiction of incorporation or organization) |
(Commission File Number) |
(I.R.S.
Employer Identification No.) |
(Address of principal executive offices) (Zip Code)
(
(Registrant’s telephone number, include area code)
N/A
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| Securities registered pursuant to Section 12(b) of the Act: | ||||
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
Item 2.02 Results of Operations and Financial Condition.
The information under the heading “Preliminary Financial Information” set forth under Item 8.01 of this Current Report on Form 8-K (this “Current Report”) is incorporated by reference into this Item 2.02.
Item 7.01 Regulation FD Disclosure.
On April 18, 2023, Immuneering Corporation (“we”, “our” and “us”) posted an updated corporate slide presentation in the “For Investors” portion of its website at www.immuneering.com. A copy of the slide presentation is furnished as Exhibit 99.1 to this Current Report.
The information in this Item 7.01 of this Current Report is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as expressly provided by specific reference in such a filing.
Item 8.01 Other Events.
Recent Developments
On April 18, 2023, we announced initial pharmacokinetic (“PK”), pharmacodynamic (“PD”) and safety data from the Phase 1 portion of our Phase 1/2a clinical trial of IMM-1-104 in patients with advanced solid tumors harboring RAS mutations.
As of April 10, 2023, we had PK, PD and safety data from four patients with pancreatic or colorectal cancer available for evaluation. Of these patients, we dosed one patient at 40 mg once daily oral dose, or the first dose level, one patient at 80 mg once daily oral dose, or the second dose level, and two patients at 160 mg once daily oral dose, or the third dose level. At the third dose level, we observed significant PK Cmax levels, which is the plasma concentration of therapy in a specific area of the body, with IMM-1-104 of over 2,000 ng/mL or approximately 1 uM drug free-fraction. In addition, we observed greater than 90% PD inhibition of phosphorylated extracellular signal-regulated kinase (pERK) with IMM-1-104 compared to pretreatment baseline for patients at the third dose level. A median plasma half-life of 1.94 hours was observed with IMM-1-104 across the first three dose levels evaluated in patients with pancreatic and colorectal cancer with different RAS mutations, including KRAS-G12D, the most common mutation present in pancreatic cancer. IMM-1-104 was well tolerated in these four patients, as well as one patient dosed at 320 mg once daily oral dose, or the fourth dose level, with no dose limiting toxicities or serious adverse events observed and no drug-related adverse events beyond Grade 1 observed.
Based on this initial data, we plan to announce the recommended Phase 2 dose in early 2024 instead of our prior guidance of mid-2024.
The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.2 to this Current Report.
Preliminary Financial Information
Based upon preliminary estimates and information available to us as of the date of this Current Report, we expect to report that we had approximately $91.5 million of cash and cash equivalents and marketable securities as of March 31, 2023. Based on our current plans, we expect that our existing cash and cash equivalents and marketable securities will enable us to fund our operating expenses and capital expenditure requirements into the fourth quarter of 2024.
We have not yet completed our financial close process for the three months ended March 31, 2023. This estimate of our cash and cash equivalents and marketable securities as of March 31, 2023 is preliminary and is subject to change upon completion of our financial statement closing procedures. There can be no assurance that our final cash position as of March 31, 2023 will not differ from this estimate, including as a result of adjustments as a result of our review, and any such change could be material. Our independent registered public accountants have not audited, reviewed or performed any procedures with respect to such preliminary financial data and accordingly do not express an opinion or any other form of assurance with respect to such data. Complete results will be included in our Quarterly Report on Form 10-Q for the three months ended March 31, 2023.
Forward-Looking Statements
This Current Report contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this Current Report that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding our cash and cash equivalents and marketable securities as of March 31, 2023, the sufficiency of our existing cash and cash equivalents and marketable securities, the treatment potential of IMM-1-104, the design, timing, enrollment criteria and conduct of the Phase 1/2a clinical trial, and the ability of initial clinical data to de-risk IMM-1-104 and be confirmed as the study progresses, including the safety, tolerability, pharmacokinetics, pharmacodynamics and potential efficacy of IMM-1-104.
These forward-looking statements are based on our current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, the risks inherent in oncology drug development, including clinical trials, and risks related to financial reporting.
These and other important factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2022 and filed with the U.S. Securities and Exchange Commission (the “SEC”) on March 6, 2023 and our other reports filed with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this Current Report. Any such forward-looking statements represent management’s estimates as of the date of this Current Report. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this Current Report.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
| Exhibit No. |
Description | |
| 99.1 | Immuneering Corporation Corporate Slide Presentation as of April 18, 2023 | |
| 99.2 | Press release issued on April 18, 2023 | |
| 104 | Cover Page Interactive Data File (embedded within the inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| IMMUNEERING CORPORATION | ||
| Date: April 18, 2023 | By: | /s/ Benjamin J. Zeskind |
| Name: | Benjamin J. Zeskind, Ph.D. | |
| Title: | Co-Founder, President, Chief Executive Officer | |
Exhibit 99.1
Building a Universal - RAS Franchise Nasdaq: IMRX APRIL 2023 Investor Presentation
2023 Corporate Presentation 2 This presentation contains forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 . All statements contained in this presentation that do not relate to matters of historical fact should be considered forward - looking statements, including, without limitation, statements regarding the Company's cash, cash equivalents and marketable securities as of March 31, 2023. In addition to the Company's plans to develop, manufacture and comme rcialize its product candidates, the treatment potential of IMM - 1 - 104, the design, enrollment criteria and conduct of the Phase 1/2a clinical trial, the translation of preclin ical data into human clinical data, the ability of initial clinical data to de - risk IMM - 1 - 104 and be confirmed as the study progresses, including the safety, tolerability, pharmacokinetic s, pharmacodynamics and potential efficacy of IMM - 1 - 104; the potential advantages and effectiveness of the company’s clinical and preclinical candidates, the timing of additiona l trial updates, recommended phase 2 dose and additional safety data, the indications to be pursued by the Company in the Phase 2a portion of the study, the timing of subm iss ion of the IND for IMM - 6 - 415, the filing with, and approval by, regulatory authorities of our product candidates, the sufficiency of funds to operate the business of the Compan y, statements regarding the Company's ability to advance its pipeline and further diversify its portfolio and make progress towards its longstanding goal of creating better m edi cines for cancer patients, the Company’s cash needs and availability, including our revenue streams, projected cash runway and current operating plans, and the plans and o bje ctives of management for future operations. These forward - looking statements are subject to a number of risks, uncertainties and assumptions, including, without limitation: our limited operating history; our history of operating losses; our ability to raise the substantial additional capital that will be required to finance our operations; th e d ifficulty of obtaining regulatory approval for any of our current or future product candidates; our ability to submit an Investigational New Drug application (“IND”), or IND amendment s o r comparable documents in foreign jurisdictions in order to commence clinical trials on the timelines we expect; our limited experience in designing and conducting clinical tri als; the timing of the initiation, progress and potential results of our ongoing and planned preclinical studies and clinical trials and our research programs, including our Ph ase 1/2a clinical trial; our ability to successfully complete our Phase 1/2a clinical trial, or any planned clinical trials and for those trials to produce positive results; the ris k of substantial delays in completing, if at all, the development and commercialization of our current or future product candidates; risks related to adverse events, toxicities or ot her undesirable side effects caused by our current or future product candidates; the risk of delays or difficulties in the enrollment and/or maintenance of patients in clinical tr ials; our substantial reliance on the successful development of our current and future product candidates, as well as our platform, including our proprietary technologies suc h a s DCT and Fluency; risks related to competition in our industry; the market opportunity for our product candidates, if approved; risks related to manufacturing; risks relate d t o our reliance on third parties; risks related to our intellectual property; and risks related to the pandemic related to COVID - 19, its variants and future pandemics. These and other important factors discussed under the caption “Risk Factors” in the Company’s Annual Report on Form 10 - K for the year ended December 31, 2022 filed with the SEC and its other reports filed with the SEC could cause actual results to differ materially from those indicated by the forw ard - looking statements made in this presentation. Any such forward - looking statements represent management’s estimates as of the date of this presentation. While the Company may elec t to update such forward - looking statements at some point in the future, it disclaims any obligation to do so, even if subsequent events cause its views to ch ang e. These forward - looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of this presentation. This presentation also contains estimates and other statistical data made by independent parties and by us relating to market si ze and other data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such data and estimates. In addition, projections, assumptions and estimates of our future performance and the future performance of the markets in which we operate are necessarily subject to a h igh degree of uncertainty and risk. Neither we nor our affiliates, advisors or representatives makes any representation as to the accuracy or completeness of that data or u nde rtake to update such data after the date of this presentation. Data of trametinib, cobimetinib , binimetinib , selumetinib , encorafenib and AMG - 510 (now known as sotorasib ) as compared to IMM - 1 - 104 presented in this presentation is based on head - to - head studies where these therapies have been purchased from commercial sources rather than the pharmaceutical company commercializing or developing, as applicable, the compound. FORWARD - LOOKING STATEMENTS AND OTHER DISCLAIMERS
Differentiated Approach • Targeting Universal - RAS patient population versus limited single mutation targeted approaches • Once - Daily Oral Dosing • Deep cyclic inhibition targeted, based on: • Manyfold higher C MAX • and short half - life • Approach designed to spare healthy cells and potential to limit adaptive resistance • Monotherapy - Focused initially, with combination potential 3 IMM - 1 - 104 Demonstrated Universal - RAS Potential Key Inflection Points Expected in Near Term • Initial Phase 1 PK, PD, safety data support profile for IMM - 1 - 104 believed to be necessary for Deep Cyclic Inhibition • Investigator enthusiasm high ; broad inclusion criteria • Additional trial updates expected on a periodic basis; RP2D expected in early 2024 • IMM - 6 - 415 IND expected in Q4 2023 • Cash runway projected into Q4 2024 • Robust preclinical activity observed in: • Pancreatic Cancer (KRAS G12C & G12V) • NSCLC (KRAS G12S) • CRC (KRAS G12D) • Melanoma (NRAS Q61R) • And others • Hypothesis for IMM - 1 - 104 from proprietary model that identified counterintuitive and novel deep cyclic inhibition approach • Validated using proprietary bioinformatics & 3D tumor growth assays
PROGRAM INDICATION DISCOVERY IND - ENABLING PHASE 1 PHASE 2 PHASE 3 ANTICIPATED MILESTONES IMM - 1 - 104 Universal - RAS Phase 1/2a Trial Enrolling; RP2D expected in early 2024 IMM - 6 - 415 Universal - MAPK IND filing expected in Q4 2023 Multiple additional programs in discovery phase Development Pipeline 4 Once Daily (QD) Twice Daily (BID) Wholly Owned Product Portfolio Differentiated by Indication and Half - life Preliminary estimated Cash, cash equivalents and marketable securities as of March 31, 2023 of $91.5M* projected to fund operations into Q4 2024 *Our actual consolidated financial results as of March 31, 2023 are not yet available. Our financial closing procedures for t he first quarter ended March 31, 2023 are not yet complete and, as a result, our final results upon completion of those procedures may differ materially from our preliminary estimates. The preliminary consolidated financial data presented above as of March 31, 2023 is not a comprehensive statement of our financia l p osition or operating results; reflects our preliminary estimates based on information available as of the date of this presentation; and is subject to chan ge, and those changes may be material. Accordingly, you should not place undue reliance upon these preliminary estimates.
IMM - 1 - 104
6 IMM - 1 - 104 Target Profile Potential for Universal - RAS Activity Deep Cyclic Inhibition ; Once - Daily Oral Dosing Short plasma half - life to minimize drug trough Initially being developed as Monotherapy Designed to Resist CRAF - bypass in RAS mutant tumors • Phase 1 recruiting all - comer RAS solid tumors: NCT05585320 • First patient dosed November 2022 • Initial Phase 1 PK, PD and safety d ata reported at AACR 2023
7 IMM - 1 - 104’s Potential: Universal - RAS * ' * $ * 5 * 6 4 * .5$62WKHU $OOQGLFDWLRQV *(1( 15$6 +5$6 .5$6 NRAS (14.12%) Targeted KRAS G12C • Based on 27,461 out of 148,268 (18.5%) patients with RAS - mutated tumors in the AACR GENIE database, v13.0 • Percentage of overall mutation shown under RAS paralogue. Select mutation percentages within KRAS are shown HRAS (2.78%) KRAS (83.10%) Compared to single - mutation targeted approaches, our Universal - RAS approach potentially addresses a much larger patient population
8 MoA Target Engagement GOAL : Prevent MAPK - pathway bypass events, for expanded activity into RAS mutant setting Near - Zero Drug Trough GOAL : Short plasma half - life to improve tolerability and limit adaptive resistance, so every day is a drug holiday Dramatic PK C MAX Pulse GOAL : Achieve many fold higher drug free fraction C MAX to break tumor addiction Deep, Cyclic Inhibition Plasma PK – 5 Day Comparison Days Conceptual illustration of deep cyclic inhibition (purple) vs. chronic pathway ablation (brown)
9 Initial Phase 1 PK, PD and Safety Data for IMM - 1 - 104 Short Half - life Observed Observed IMM - 1 - 104 half - life of approximately 2 hours, as projected in Immuneering’s preclinical modeling Deep Cyclic Inhibition (DCI) Initial pharmacokinetic (PK), pharmacodynamic (PD) and safety data support profile for IMM - 1 - 104 believed to be necessary for Deep Cyclic Inhibition (DCI) Significant PK C MAX Significant levels of PK C MAX observed (~1uM free fraction C MAX at 160 mg QD p.o. doses) Safety Data IMM - 1 - 104 well tolerated with no dose - limiting toxicities (DLTs) or serious adverse events (SAEs) observed RP2D Recommended Phase 2 Dose (RP2D) now expected in early 2024 Trial Timeline Acceleration Potentially therapeutic doses of IMM - 1 - 104 now likely to be reached earlier than previously planned due to acceleration of trial timeline Clinical data timeline reported through April 10th, 2023 (i.e., ~20 weeks since first patient dosed) First demonstration of novel deep cyclic inhibition mechanism in humans
10 Patient Status Summary for IMM - 1 - 104 Phase 1 Dose Escalation Clinical data timeline reported through April 10th, 2023 (i.e., ~20 weeks since first patient dosed) # Patient RAS Mutation Dose Level Dose C1D1 (t 1/2 ) C1D15 (t 1/2 ) Mean (t 1/2 ) IMM - 1 - 104 Status 1. PANCREATIC KRAS - G12D I 40 mg QD p.o. 1.82 hours 2.10 hours 1.96 hours Off Treatment 2. COLORECTAL KRAS - G12V II 80 mg QD p.o. 1.41 hours 1.43 hours 1.42 hours Off Treatment 3. COLORECTAL NRAS - Q61L III 160 mg QD p.o. 2.04 hours 1.83 hours 1.94 hours Off Treatment 4. COLORECTAL NRAS - Q61K III 160 mg QD p.o. 1.91 hours 1.97 hours 1.94 hours On Treatment 5. PANCREATIC KRAS - G12D IV 320 mg QD p.o. t.b.d. t.b.d. t.b.d. On Treatment • No DLTs or SAEs observed; No drug - related AEs beyond grade 1 have been reported in dose levels III or IV • Early PK data were approximately dose linear with no drug accumulation • Actively enrolling patients at 320 mg QD p.o. with 2 additional patients already consented (KRAS - G12V Pancreatic and KRAS - G12S Colorectal)
0 3 6 9 12 15 18 21 24 0 250 500 750 1000 1250 1500 1750 2000 2250 2500 0 10 20 30 40 50 60 70 80 90 100 Time (hours) I M M - 1 - 1 0 4 [ n g / m L ] AACR poster PK/PD: Pt.3 & Pt.4 ERK % Baseline Pt.3 PK (ng/mL) p h o s p h o : t o t a l - E R K ( % B a s e l i n e ) Pt.4 PK (ng/mL) Pt.3 p/t-ERK (% baseline) Pt.4 p/t-ERK (% baseline) 87 - 92% ↓ p/t - ERK C max ≳ 2,000 ng/mL C min ≳ 6 - 8 hours 11 ~ 90% Pharmacodynamic Inhibition of pERK • Dose Level III: Cycle 1 Day 1 (C1D1) PK (solid), BK (dotted), and PD (dotted) for patient 3 ( purple ) and 4 ( blue ), both at 160 mg QD p.o. • PK plasma: pre - dose (0), 0.5, 1, 1.5, 2*, 4, 6, 8, 24 hours; PD plasma: PK - matched without 0.5 or 1.5 hours (*poor sample qualit y for Pt.4 at 2 hour) • PD method: A549 (KRAS G12S ) cells were exposed to patient plasma for 2 - hours before quantifying phosphorylated and total ERK and MEK 0 3 6 9 12 15 18 21 24 0 250 500 750 1000 1250 1500 1750 2000 2250 2500 0 10 20 30 40 50 60 70 80 90 100 Time (hours) I M M - 1 - 1 0 4 [ n g / m L ] AACR poster PK/PD: Pt.3 & Pt.4 MEK % Baseline Pt.3 PK (ng/mL) p h o s p h o : t o t a l - M E K ( % B a s e l i n e ) Pt.4 PK (ng/mL) Pt.3 p/t-MEK (% baseline) Pt.4 p/t-MEK (% baseline) IMM - 1 - 104 PK/PD (pMEK) data shows suppression of pathway bypass 55 - 59% ↓ p/t - MEK C max ≳ 2,000 ng/mL C min ≳ 6 - 8 hours ≥ 90% MEK occupancy PK: C max ≳ 1 μM FF PK: C min ≳ 6 - 8 hours Modeled PK/BK, Drug Free - Fraction (FF) † shows high Cmax † Hoare, Sam RJ. "Analyzing kinetic binding data." Assay Guidance Manual [Internet] (2021) IMM - 1 - 104 PK/PD (pERK) shows MAPK pathway suppression
IMM - 1 - 104: Phase 1/2 Clinical Trial Plan * Solid tumor, all comer with evidence of RAS mutation ** Simon 2 - Stage Design. Proposed tumor types may change based upon preclinical PGx studies and clinical function review First Time in Humans • RAS mutated Pancreatic (PAAD) (~ 40 pts) • RAS Mutated NSCLC - Adeno (~40 pts) • RAS Mutated, APC wt CRC (~40 pts) • RAS Mutated Melanoma (~40 pts) • RP2D = Recommended Phase 2 Dose • PGx = Pharmacogenomics IND cleared; First patient dosed on Nov 21, 2022 Expansion 2: Expansion 1: Expansion 3 & 4: biomarker stratification Dose Expansion - Phase 2 a ** Dose Escalation Phase 1a * 12 IMM - 1 - 104 (Dual MEK inhibitor) Bayesian Design (mTPI - 2) e scalation in select solid tumor types* Dose Evaluation and RP2D Dose Evaluation Phase 1b* ≤12 patients expected ~12 - 20 patients expected ; “bake off” between dose levels per Project Optimus
13 Phase 1 Sites ClinicalTrials.gov Identifier: NCT05585320 MD Anderson Cancer Center › Houston, Texas, United States, 77030 › Principal Investigator: Shubham Pant, MD United States, Texas NEXT Oncology › San Antonio, Texas, United States. 78229 › Principal Investigator: David Sommerhalder , MD MD Weill Cornell Medicine › New York, New York, United States, 10021 › Principal Investigator: Anna Pavlick, DO United States, New York City of Hope › Duarte, California, United States, 91010 › Principal Investigator: Vincent Chung, MD United States, California NEXT Oncology › Fairfax, Virginia, United States, 22031 › Principal Investigator: Alex Spira , MD, PhD United States, Virginia • Investigator enthusiasm remains high • Broad RAS inclusion criteria (Solid Tumors, All Histologies )
IMM - 1 - 104 Preclinical Data
IMM - 1 - 104 Demonstrated Universal - RAS Potential 15 Humanized 3D - TGA RAS, RAF mutation Response # Non - Response # NRAS G12 2 0 NRAS G13 1 0 NRAS Q61 17 2 KRAS A146 1 0 KRAS G12 36 8 KRAS G13 ^ 3 1 KRAS Q61 3 0 HRAS G13 * 1 0 BRAF (Class I or II) 21 4 Total 85 (85.0%) 15 (15.0%) ^ 1 model also bearing KRAS Q61 /// * 1 model also bearing NRAS Q61 RAS, RAF mutation Response # Non - Response # Not Present 17 15 Total 17 (53.1%) 15 (46.9%) Response to IMM - 1 - 104 based on 3D - TGA and other preclinical modeling. Parallel translational efforts are focused on projecting p atient - aligned molecular profiles or ‘Targetability’. # Models tested in 3D - TGA were assigned responsive if dose response IC50 < 1uM (sensitive) or IC50 ≥ 1 with >25% reduction at 10uM (intermediate), and non - responsive otherwise (resistant) † Select 3D - TGA models: (1.) Pancreatic MIA PaCa - 2 (sensitive/responsive), (2.) Pancreatic Capan - 2 (intermediate/responsive), (3.) Melanoma SK - MEL - 2 (sensitive/responsive), (4.) Lung A549 (intermediate/responsive) Tissue Response # Non - Response # Pancreatic † 17 2 Melanoma † 22 0 Lung † 19 6 CRC 20 5 Thyroid 6 1 Soft Tissue 2 1 Breast 2 6 Gastric 4 2 Ovary 3 2 Prostate 1 2 Fibrosarcoma 1 0 Liver 4 2 Neuroblastoma 1 1 Total 102 (77.3%) 30 (22.7%) Kolitz, et al. 2023 AACR: Targeting RAS Philadelphia, PA 132 Tumor Models 75 = RAS Mutant
Humanized 3D - TGA Pharmacogenomics (PGx) Modeling 16 Nair, et al. 2023, AACR: National Meeting, Orlando, FL • Cell lines tested in 3D - TGA (N=132) were assigned response of sensitive (IC50 < 1uM), intermediate (IC50 ≥ 1 and >25% reduction at 10uM), and resistant otherwise • The dark line on each plot represents the median of the individual curves • Vertical gray boxes match C max IMM - 1 - 104 drug free - fractions attained in patients 3 and at 160 mg QD p.o. (both at Dose Level 3 in Phase 1 trial) 0 25 50 75 100 1 10 100 1000 10000 Dose (nM) % E d U ( N o r m a l i z e d t o V e h i c l e C o n t r o l ) 3D TGA Results − Gold Standard IMM−1−104 0 25 50 75 100 1 10 100 1000 10000 Dose (nM) % E d U ( N o r m a l i z e d t o V e h i c l e C o n t r o l ) 3D TGA Results − Gold Standard IMM−1−104 N = 38 Models N = 64 Models N = 30 Models Sensitive Intermediate Resistant Attained Clinical Free Fraction C max of ~1 uM Aligns with 3D - TGA Response Categorization
IMM - 1 - 104 Demonstrated Universal - RAS Potential ELN: PJK03-0013PK 0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 0 250 500 750 1000 1250 1500 1750 2000 2250 2500 2750 3000 3250 3500 Time (days) T u m o r v o l u m e ( M e d i a n ± Q u a r t i l e ; m m 3 ) **Data: TV (mm3) - 100 + 150 mpk - IMM-1-104 MEDIAN Vehicle 0 mg/kg BID po MEDIAN 150 mg/kg IMM-01-00104 BID po MEDIAN 100 mg/kg IMM-01-00104 BID po IMM-1-104 (TGI = 76%) (TGI = 90%) 0 3 6 9 12 15 18 21 0 50 100 150 200 250 300 350 400 450 500 550 600 650 700 Time (days) T u m o r v o l u m e ( M e d i a n ± Q u a r t i l e ; m m 3 ) Copy of __Pres Data: TV (mm3) - Dose Range - IMM-01-00104 MEDIAN: 0 mg/kg Vehicle QD po : 0 mg/kg Vehicle BID po MEDIAN: 0 mg/kg Vehicle QD po : 100 mg/kg IMM-1-104 BID po MEDIAN: 0 mg/kg Vehicle QD po : 150 mg/kg IMM-1-104 BID po MIA PaCa - 2 N=12 TGI Day21 = 122% TGI Day21 = 108% KRAS G12C PANC 0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 0 250 500 750 1000 1250 1500 1750 2000 2250 2500 Time (days) T u m o r v o l u m e ( M e d i a n ± Q u a r t i l e ; m m 3 ) **Data: TV (mm3) - 100 + 150 mpk - IMM-1-104 MEDIAN Vehicle 0 mg/kg BID po MEDIAN 150 mg/kg IMM-01-00104 BID po MEDIAN 100 mg/kg IMM-01-00104 BID po A - 549 N=12 TGI Day28 = 95% TGI Day28 = 91% KRAS G12S NSCLC Colon - 26 N=8 TGI Day10 = 108% TGI Day10 = 84% KRAS G12D CRC SK - MEL - 2 N=12 0 3 6 9 12 15 18 21 0 100 200 300 400 500 600 700 800 900 1000 Time (days) T u m o r v o l u m e ( M e d i a n ± Q u a r t i l e ; m m 3 ) Mic Drop Panel: TV (mm3) - DR IMM-1-104 MEDIAN: 0 mg/kg Vehicle BID po MEDIAN: 100 mg/kg IMM-1-104 BID po MEDIAN: 125 mg/kg IMM-1-104 BID po MEDIAN: 150 mg/kg IMM-1-104 BID po TGI Day21 = 100% TGI Day21 = 75% TGI Day21 = 91% NRAS Q61R MEL CRC = colorectal cancer; NSCLC = non - small cell lung cancer; MEL = melanoma; PANC = pancreatic cancer Maximum Effective Dose Range in Mice (plasma t 1/2 = 1.3 hours) is 100 mg/kg to 150 mg/kg BID po Tumor Growth Inhibition (TGI) % = [1 – (Ti – T0)/(Ci – C0)]x100 ; T = treatment groups ; C = control groups *Well - tolerated at top doses with no more than 3 - 6% median body weight loss (BWL) ** Capan - 2 PANC model, as reported at ASCO 2022 (0% TGI for sotorasib and adagrasib at top doses) Well Tolerated : Median Body Weight Loss ≤ 3 - 6%* of baseline at top doses 17 ELN: PJK03-0013PK 0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 0 250 500 750 1000 1250 1500 1750 2000 2250 2500 2750 3000 3250 3500 Time (days) T u m o r v o l u m e ( M e d i a n ± Q u a r t i l e ; m m 3 ) **Data: TV (mm3) - 100 + 150 mpk - IMM-1-104 MEDIAN Vehicle 0 mg/kg BID po MEDIAN 150 mg/kg IMM-01-00104 BID po MEDIAN 100 mg/kg IMM-01-00104 BID po IMM-1-104 (TGI = 76%) (TGI = 90%) N=12 KRAS G12V PANC 0 3 6 9 12 15 18 21 0 50 100 150 200 250 300 350 400 450 500 550 600 650 Time (days) T u m o r v o l u m e ( M e d i a n ± Q u a r t i l e ; m m 3 ) Copy of BID Data: TV (mm3) - IMM-1-104 MEDIAN: 0 mg/kg Vehicle BID po MEDIAN: 100 mg/kg IMM-1-104 BID po MEDIAN: 150 mg/kg IMM-1-104 BID po CAPAN-2 (KRAS-G12V) Capan - 2 TGI Day21 = 84 % TGI Day21 = 61 % IMM - 1 - 104 demonstrated significant and consistent Tumor Growth Inhibition (TGI)
Pancreatic: Head - to - Head Comparison of IMM - 1 - 104 +/ - Sotorasib in a KRAS - G12C Pancreatic Tumor Model MIA PaCa - 2 (KRAS G12C ) Pancreatic Xenograft Tumor Model in Athymic Nude Mice Sotorasib was commercially purchased Tumor Growth Inhibition (TGI) % = [1 – (T i – T 0 )/(C i – C 0 )]x100%; Expanded TGI formula vs. previous 1 - [T/C]x100% method IMM - 1 - 104 as compared to sotorasib demonstrated tumor regression, both with insignificant BWL 18 (N=12, per group) 0 3 6 9 12 15 18 21 0 50 100 150 200 250 300 350 400 450 500 550 600 650 700 750 Time (days) T u m o r v o l u m e ( M e d i a n ± I n t e r q u a r t i l e ; m m 3 ) Copy of __Pres Data: TV (mm3) - 100 - AMG-510 MEDIAN: 0 mg/kg Vehicle QD po : 0 mg/kg Vehicle BID po MEDIAN: 100 mg/kg AMG-510 QD po : 0 mg/kg Vehicle BID po Median Body Weight Loss 0% of Baseline 100 mg/kg Shown (N=12, per group) 0 3 6 9 12 15 18 21 0 50 100 150 200 250 300 350 400 450 500 550 600 650 700 750 Time (days) T u m o r v o l u m e ( M e d i a n ± I n t e r q u a r t i l e ; m m 3 ) Copy of __Pres Data: TV (mm3) - 150 mg - IMM-01-00104 MEDIAN: 0 mg/kg Vehicle QD po : 0 mg/kg Vehicle BID po MEDIAN: 0 mg/kg Vehicle QD po : 150 mg/kg IMM-1-104 BID po 0 3 6 9 12 15 18 21 0 50 100 150 200 250 300 350 400 450 500 550 600 650 700 750 Time (days) T u m o r v o l u m e ( M e d i a n ± I n t e r q u a r t i l e ; m m 3 ) Copy of __Pres Data: TV (mm3) - 150 mg - IMM-01-00104 MEDIAN: 0 mg/kg Vehicle QD po : 0 mg/kg Vehicle BID po MEDIAN: 0 mg/kg Vehicle QD po : 150 mg/kg IMM-1-104 BID po (N=12, per group) Median Body Weight Loss < 1.8% of Baseline 150 mg/kg Shown (N=12, per group) 0 3 6 9 12 15 18 21 0 50 100 150 200 250 300 350 400 450 500 550 600 650 700 750 Time (days) T u m o r v o l u m e ( M e d i a n ± I n t e r q u a r t i l e ; m m 3 ) __Data: TV (mm3) - ALL combinations together 0 mg/kg Vehcile QD po : 0 mg/kg Vehicle BID po 30 mg/kg AMG-510 QD po : 50 mg/kg IMM-1-104 BID po 30 mg/kg AMG-510 QD po : 100 mg/kg IMM-1-104 BID po 30 mg/kg AMG-510 QD po : 150 mg/kg IMM-1-104 BID po IMM - 1 - 104 : Sotorasib 0 : 0 0 : 30 150 : 0 150 : 30 NO TREATMENT + 21 Days 0 3 6 9 12 15 18 21 0 50 100 150 200 250 300 350 400 450 500 550 600 650 700 750 Time (days) T u m o r v o l u m e ( M e d i a n ± I n t e r q u a r t i l e ; m m 3 ) __Data: TV (mm3) - ALL combinations together 0 mg/kg Vehicle QD po : 0 mg/kg Vehicle BID po 30 mg/kg sotorasib QD po : 50 mg/kg IMM-1-104 BID po 30 mg/kg sotorasib QD po : 100 mg/kg IMM-1-104 BID po 30 mg/kg sotorasib QD po : 150 mg/kg IMM-1-104 BID po TREATMENT 21 Days Median Body Weight < 1.0% of baseline at top dose combination IMM - 1 - 104 : Sotorasib 50 : 30 100 : 30 150 : 30 Sotorasib 10 - 30 - 100 mg/kg QD p.o.) IMM - 1 - 104 + Sotorasib (50 - 100 - 150 mg/kg BID + 30 mg/kg QD) IMM - 1 - 104 (50 - 100 - 150 mg/kg BID p.o.) IMM - 1 - 104 + Sotorasib (150 mg/kg BID + 30 mg/kg QD) 0 3 6 9 12 15 18 21 0 50 100 150 200 250 300 350 400 450 500 550 600 650 700 750 Time (days) T u m o r v o l u m e ( M e d i a n ± I n t e r q u a r t i l e ; m m 3 ) __Pres Data: TV (mm3) - 100 - AMG-510 100 mg/kg AMG-510 QD po : 0 mg/kg Vehicle BID po MEDIAN: 0 mg/kg Vehicle QD po : 0 mg/kg Vehicle BID po MEDIAN: 100 mg/kg sotorasib QD po : 0 mg/kg Vehicle BID po TGI top - combo = 131% TGI = 122% TGI = 127%
Pancreatic: Head - to - Head Comparison of IMM - 1 - 104 vs. Sotorasib and Adagrasib in a KRAS - G12V Pancreatic Tumor Model IMM - 1 - 104 demonstrated tumor regression as compared to no reduction with sotorasib or adagrasib , with insignificant BWL 19 Adagrasib (30, 100 mg/kg QD p.o.) IMM - 1 - 104 (100, 150 mg/kg BID p.o.) Sotorasib (30, 100 mg/kg QD p.o.) 0 3 6 9 12 15 18 21 0 50 100 150 200 250 300 350 400 450 500 550 600 650 700 750 Time (days) T u m o r v o l u m e ( M e d i a n ± Q u a r t i l e ; m m 3 ) Copy of BID Data: TV (mm3) - IMM-1-104 MEDIAN: 0 mg/kg Vehicle BID po MEDIAN: 100 mg/kg IMM-1-104 BID po MEDIAN: 150 mg/kg IMM-1-104 BID po CAPAN-2 (KRAS-G12V) 0 3 6 9 12 15 18 21 0 50 100 150 200 250 300 350 400 450 500 550 600 650 700 750 Time (days) T u m o r v o l u m e ( M e d i a n ± Q u a r t i l e ; m m 3 ) Copy of BID Data: TV (mm3) - IMM-1-104 MEDIAN: 0 mg/kg Vehicle BID po MEDIAN: 100 mg/kg IMM-1-104 BID po MEDIAN: 150 mg/kg IMM-1-104 BID po CAPAN-2 (KRAS-G12V) 0 3 6 9 12 15 18 21 0 50 100 150 200 250 300 350 400 450 500 550 600 650 700 750 Time (days) T u m o r v o l u m e ( M e d i a n ± Q u a r t i l e ; m m 3 ) QD Data: TV (mm3) - AMG-510 Sotorasib MEDIAN: 0 mg/kg Vehicle QD po MEDIAN: 30 mg/kg sotorasib QD po MEDIAN: 100 mg/kg sotorasib QD po CAPAN-2 (KRAS-G12V) (N=12, per group) (N=12, per group) (N=12, per group) 0 3 6 9 12 15 18 21 0 50 100 150 200 250 300 350 400 450 500 550 600 650 700 750 Time (days) T u m o r v o l u m e ( M e d i a n ± Q u a r t i l e ; m m 3 ) QD Data: TV (mm3) - AMG-510 Sotorasib MEDIAN: 0 mg/kg Vehicle QD po MEDIAN: 30 mg/kg sotorasib QD po MEDIAN: 100 mg/kg sotorasib QD po CAPAN-2 (KRAS-G12V) Capan - 2 (KRAS G12V ) Pancreatic Xenograft Tumor Model in Athymic Nude Mice Sotorasib and adagrasib were commercially purchased Tumor Growth Inhibition (TGI) % = [1 – (T i – T 0 )/(C i – C 0 )]x100%; Expanded TGI formula vs. previous 1 - [T/C]x100% method Median Body Weight Loss 0% of Baseline Median Body Weight Loss 0% of Baseline Median Body Weight Loss <5.8% of Baseline
Dummer, et al 2017 Lancet S1470 - 2045 (17) 30180 - 8 2.8 months 1.5 months 11.0 months 10.1 months Binimetinib Dacarbazine Hazard Ratio Progression Free Survival Overall Survival 0.62 1.00 NRAS Status Binimetinib Dacarbazine N = 269 N = 133 Q61K 100 (37%) 51 (38%) Q61L 32 (12%) 17 (13%) Q61R 137 (51%) 64 (48%) Wildtype 0 1 (1%) Serious Adverse Events (34% binimetinib vs. 22% dacarbazine) Overall Response Rate (ORR: 15% binimetinib vs. 7% dacarbazine) Melanoma: Phase 3 NEMO Study: Binimetinib vs. Dacarbazine (NRAS mut Melanoma) Summary of Phase 3 NEMO study of Binimetinib as reported in Lancet (c.2017) - a potential opportunity for IMM - 1 - 104 20 2: 1
Melanoma: Head - to - Head NRAS - Q61R Melanoma Xenograft Study: Binimetinib vs. IMM - 1 - 104 in SK - MEL - 2 IMM - 1 - 104 as compared to binimetinib monotherapy demonstrated greater tumor growth inhibition (TGI) SK - MEL - 2 (NRAS - Q61R) Melanoma Xenograft Tumor Model in Athymic Nude Mice CRAF - bypass IMM - 1 - 104 (100 - 125 - 150 mg/kg BID p.o.) Binimetinib (3 - 10 - 30 mg/kg BID p.o.) 0 1 2 3 4 5 6 7 8 9 10111213141516171819202122 0 100 200 300 400 500 600 700 800 900 1000 Time (days) T u m o r v o l u m e ( M e d i a n ± I n t e r q u a r t i l e ; m m 3 ) SK-MEL-2 (NRAS-mutant MEL) - IMM-1-104 MEDIAN: 0 mg/kg Vehicle BID po MEDIAN: 100 mg/kg IMM-1-104 BID po MEDIAN: 125 mg/kg IMM-1-104 BID po MEDIAN: 150 mg/kg IMM-1-104 BID po 0 1 2 3 4 5 6 7 8 9 10111213141516171819202122 0 100 200 300 400 500 600 700 800 900 1000 Time (days) T u m o r v o l u m e ( M e d i a n ± I n t e r q u a r t i l e ; m m 3 ) SK-MEL-2 (NRAS-mutant MEL) - Binimetinib MEDIAN: 0 mg/kg Vehicle BID po MEDIAN: 3 mg/kg Binimetinib BID po MEDIAN: 10 mg/kg Binimetinib BID po MEDIAN: 30 mg/kg Binimetinib BID po 0 1 2 3 4 5 6 7 8 9 10111213141516171819202122 0 100 200 300 400 500 600 700 800 900 1000 Time (days) T u m o r v o l u m e ( M e d i a n ± I n t e r q u a r t i l e ; m m 3 ) SK-MEL-2 (NRAS-mutant MEL) - IMM-1-104 MEDIAN: 0 mg/kg Vehicle BID po MEDIAN: 100 mg/kg IMM-1-104 BID po MEDIAN: 125 mg/kg IMM-1-104 BID po MEDIAN: 150 mg/kg IMM-1-104 BID po N=12, per group N=12, per group TGI = 100% TGI = 91% TGI = 75% TGI = 35% 21 Binimetinib was commercially purchased
CRC: Head - to - Head Comparison of IMM - 1 - 104 Against Selumetinib and Binimetinib in a KRAS - G12D CRC Syngeneic Mouse Tumor Model 0 3 6 9 12 15 18 21 24 27 0 250 500 750 1000 1250 1500 1750 2000 2250 2500 Time (days) T u m o r v o l u m e ( M e d i a n ± Q u a r t i l e ; m m 3 ) Data: TV (mm3) - Selumetinib - 50 only Vehicle 0 mg/kg BID po 50 mg/kg BID po Selumetinib 50 mg/kg BID po Selumetinib - Individual 0 3 6 9 12 15 18 21 24 27 0 250 500 750 1000 1250 1500 1750 2000 2250 2500 Time (days) T u m o r v o l u m e ( M e d i a n ± Q u a r t i l e ; m m 3 ) Data: TV (mm3) - Binimetinib - 30 dose only Vehicle 0 mg/kg BID po 30 mg/kg BID po Binimetinib 30 mg/kg BID po Binimetinib - Individual Colon - 26 (KRAS - G12D) Syngeneic Colorectal Tumor Model in Balb/c Mice Selumetinib and binimetinib were commercially purchased Tumor Growth Inhibition (TGI) % = [1 – (Ti – T0)/(Ci – C0)]x100%; Expanded TGI formula vs. previous 1 - [T/C]x100% method IMM - 1 - 104 demonstrated greater tumor growth inhibition (TGI), lower body weight loss (BWL) and greater durability via reductions in tumor volume (TV) IMM - 1 - 104 (Clinical) Binimetinib (FDA approved) Selumetinib (FDA approved) 22 N=8, per group N=8, per group N=8, per group
IMM - 6 - 415
IMM - 6 - 415: Monotherapy Activity in RAF and RAS Mutant Tumors Colon - 26 A - 549 SK - MEL - 2 A - 375 KRAS G12S NSCLC KRAS G12D CRC NRAS Q61R MEL BRAF V600E MEL CRC = colorectal cancer; NSCLC = non - small cell lung cancer; MEL = melanoma SITC 2022 Presentation: Maximum Effective Dose Range in Mice ( plasma t 1/2 = 0. 3 to 0.4 hours ): 150 - 180 mg/kg BID Well Tolerated up to Maximum Monotherapy Effective Dose Range of 150 to 180 mg/kg 24 Model HRAS NRAS BRAF NF1 3D-TGA SK-MEL-2 p.Q61R MM127 p.G13R p.G464E n.t. MM415 p.Q61L n.t. MEL-JUSO p.G13D p.Q61L n.t. SK-MEL-30 p.Q61K n.t. Hs852T p.G12V n.t. MeWo LoF n.t. A375 p.V600E SK-MEL-28 p.V600E 3D - Tumor Growth Assay (3D - TGA) sensitivity (green) SK - MEL - 28 BRAF V600E MEL 0 2 4 6 8 10 12 14 16 18 20 22 0 200 400 600 800 1000 1200 1400 1600 Time (days) T u m o r v o l u m e ( M e d i a n ± Q u a r t i l e o r I n d i v i d u a l ; m m 3 ) A549 (KRAS G12S ) 180 mg/kg BID PO MEDIAN: IMM-6-415, 180mg/kg, 10ul/g, p.o., BID × 21 MEDIAN: Vehicle, 0mg/kg, 10ul/g, p.o., BID x 21 IMM-6-415, 180mg/kg, 10ul/g, p.o., BID × 21 N = 12 mice per group ** **** ** P = 0.0015; day 7 **** P < 0.0001; day 10-21 **** **** **** 1104 mm 3 197 mm 3 138 mm 3 2-way ANOVA followed by Tukey for mulitple comparisons
Accelerated Cadence of IMM - 6 - 415 Enhanced Activity of Checkpoint Inhibitors Cyclic disruption of MEK improved overall survival with check point inhibitors (SITC 2022) 25 Schedule Dose (mg/kg) Veh ⍺ PD - 1 (BIW) ⍺ CTLA - 4 (BIW) IMM - 6 - 415 IMM - 6 - 415 + PD - 1 IMM - 6 - 415 + CTLA - 4 BID 120 0/12 7/12 11/12 10/12 BID 60 0/12 0/12 8/12 8/12 BID 30 0/12 0/12 5/12 5/12 QD 120 0/12 0/12 7/12 7/12 QD 60 0/12 1/12 4/12 8/12 QD 30 0/12 0/12 6/12 7/12 BIW 10 0/12 4/12 BIW 10 0/12 4/12 • Number of BALB/c mice (out of 12) with tumors through Day 28 with volumes lower than 2,000 mm 3 Monotherapy Treated Alive at Day 28 Combination ≥ 3 Advantage Syngeneic CT - 26 Model KRAS G12D CRC Presented at SITC (Nov. 2022): RAS wild type MC38 IO model ≥3 advantage only observed in IMM - 6 - 415 (120 p.o. BID) + anti - PD - 1
Corporate
• Preliminary estimated Cash, cash equivalents and marketable securities as of March 31, 2023: $91.5M* • Cash runway projected into Q4 2024 supports: • IMM - 1 - 104: • Multiple data readouts from Phase 1/2a trial • IMM - 6 - 415: • Anticipate IND filing in Q4 2023 • Research in additional oncology programs 27 Finance & Intellectual Property Finance Intellectual Property** Patents issued/pending: • Pending U.S. and ex - U.S. applications relating to IMM - 1 - 104 • Pending U.S. provisional and PCT applications relating to IMM - 6 - 415 • Issued U.S. patent and pending application relating to DCT • Pending U.S. applications to Fluency Expected patent expiration: (excluding patent term adjustments, etc.) • IMM - 1 - 104 = 2041 • IMM - 6 - 415 = 2043 • DCT = 2039 • Fluency = 2039 *Our actual consolidated financial results as of March 31, 2023 are not yet available. Our financial closing procedures for t he first quarter ended March 31, 2023 are not yet complete and, as a result, our final results upon completion of those procedures may differ materially from our preliminary estimates. Th e preliminary consolidated financial data presented above as of March 31, 2023 is not a comprehensive statement of our financial position or operating results; reflects our prel imi nary estimates based on information available as of the date of this presentation; and is subject to change, and those changes may be material. Accordingly, you should not place un due reliance upon these preliminary estimates. **As reported in the Company's most recent Annual Report on Form 10 - K filed with the SEC
28 Milestones Program Milestone Expected Timing IMM - 1 - 104 Initial Phase 1 pharmacokinetic (PK) and safety data COMPLETE IMM - 1 - 104 Initial Phase 1 pharmacodynamic (PD) modeling data and additional PK and safety data COMPLETE IMM - 1 - 104 Additional trial updates On a periodic basis IMM - 1 - 104 RP2D and Additional Safety data Early 2024 IMM - 6 - 415 IND filing Q4 2023
Differentiated Approach • Targeting Universal - RAS patient population versus limited single mutation targeted approaches • Once - Daily Oral Dosing • Deep cyclic inhibition targeted, based on: • Manyfold higher C MAX • and short half - life • Approach designed to spare healthy cells and potential to limit adaptive resistance • Monotherapy - Focused initially, with combination potential 29 IMM - 1 - 104 Demonstrated Universal - RAS Potential Key Inflection Points Expected in Near Term • Initial Phase 1 PK, PD, safety data support profile for IMM - 1 - 104 believed to be necessary for Deep Cyclic Inhibition • Investigator enthusiasm high ; broad inclusion criteria • Additional trial updates expected on a periodic basis; RP2D expected in early 2024 • IMM - 6 - 415 IND expected in Q4 2023 • Cash runway projected into Q4 2024 • Robust preclinical activity observed in: • Pancreatic Cancer (KRAS G12C & G12V) • NSCLC (KRAS G12S) • CRC (KRAS G12D) • Melanoma (NRAS Q61R) • And others • Hypothesis for IMM - 1 - 104 from proprietary model that identified counterintuitive and novel deep cyclic inhibition approach • Validated using proprietary bioinformatics & 3D tumor growth assays
Appendix Nasdaq: IMRX April 2023
Our Platform Converts Gene Expression to Counterintuitive Insights Goal: achieve broader activity and better tolerability in RAS and beyond mutant disease Disease Cancellation Disease Amplification Disease Cancellation Disease Amplification 1 st generation MEKi 1 st generation MEKi IMRX Disease Cancelling Technology - US Patent 11,043,305 Unlike first generation MEK inhibitors, IMM - 1 - 104 is designed to prevent RAF - and KSR - mediated activation of MEK (i.e., CRAF - bypass) and displays a short plasma half - life to potentially drive deep cyclic inhibition of the pathway. Data - driven Identification and Optimization of New Medicines to Cancel Cancer Cachexia Presented by Ben Zeskind at the 12 th International Conference of Cachexia, Sarcopenia & Muscle Wasting (SCWD) in Berlin, Dec. 6 - 8, 2019 31 Cancer Cell Growth RAS RAF MEK ERK NF1 OFF ON RAS NANOCLUSTERS P P P P P P P MEK inh RTK
Deep Cyclic Inhibition Demonstrated Using Transcriptomics Traditional Approach Signaling Dynamics Chronic Suppression → TOXICITY Cyclic Disruption → TOLERABILITY 32 Syngeneic Colon - 26 study (18 days BID dosing; tumor RNA) Syngeneic Colon - 26 study (18 days BID dosing; tumor RNA)
IMM - 1 - 104 is a Dual - MEK Inhibitor Goal deep, cyclic inhibition with ability to prevent MEK - reactivation (improve tolerability and activity) Short plasma half - life to minimize drug trough (~ 1 to 2 hours t 1/2 ) Resists CRAF - bypass in RAS mutant tumors (↓ pERK and pMEK) Ideal Dosing Schedule: ≥ 7 - 8 half lives between doses (BID for < 1.5 hr t 1/2 ; QD for 2 to 3 hr t 1/2 ) IMM - 1 - 104 Mechanism Half - Life + 33 Cadence
Head - to - Head Comparison of IMM - 1 - 104 Against FDA - Approved MEK Inhibitors: CRAF - Bypass Resistance FDA - Approved MEK inhibitors: Trametinib, Cobimetinib, Binimetinib, Selumetinib commercially purchased 1.00 0.03 0.19 0.17 0.21 0.29 1.00 1.24 6.46 2.96 2.45 0.56 0.01 0.10 1.00 10.00 0.1% DMSO Trametinib Cobimetinib Binimetinib Selumetinib IMM-1-104 p - P r o t e i n : t o t a l P r o t e i n ( N o r m a l i z e d t o D M S O ) Drug Dose = 100 nM (2 hours exposure; A549) A549 KRAS-mut Lung Cancer: pERK and pMEK pERK pMEK CRAF-bypass if > 1.0 Decreased activity for both MEK & ERK A549 KRAS - mut Lung Cancer: pERK and pMEK CRAF Bypass > 1.0 34 Cancer Cell Growth RAS RAF MEK ERK NF1 OFF ON RAS NANOCLUSTERS P P P P P P P MEK inh RTK
Head - to - Head Comparison of IMM - 1 - 104 Against Binimetinib +/ - Encorafenib in KRAS - G12S NSCLC Tumor Model A549 (KRAS G12S ) NSCLC Xenograft Tumor Model in Athymic Nude Mice Tumor Growth Inhibition (TGI) % = [1 – ( T i – T 0 )/(C i – C 0 )]x100%; Expanded TGI formula vs. previous 1 - [T/C]x100% method Human Dose Equivalent (HDE) binimetinib = 1 - 3 mg/kg BID IMM - 1 - 104 as compared to binimetinib monotherapy demonstrated greater tumor growth inhibition (TGI) Binimetinib and encorafenib were commercially purchased IMM - 1 - 104 (150 mg/kg BID p.o.) (N=12, per group) 0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 0 250 500 750 1000 1250 1500 1750 2000 2250 2500 Time (days) T u m o r v o l u m e ( M e d i a n ± Q u a r t i l e ; m m 3 ) **Data: TV (mm3) - 100 + 150 mpk - IMM-1-104 MEDIAN Vehicle 0 mg/kg BID po MEDIAN 150 mg/kg IMM-01-00104 BID po MEDIAN 100 mg/kg IMM-01-00104 BID po 0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 0 250 500 750 1000 1250 1500 1750 2000 2250 2500 Time (days) T u m o r v o l u m e ( M e d i a n ± Q u a r t i l e ; m m 3 ) **Data: TV (mm3) - 100 + 150 mpk - IMM-1-104 MEDIAN Vehicle 0 mg/kg BID po MEDIAN 150 mg/kg IMM-01-00104 BID po MEDIAN 100 mg/kg IMM-01-00104 BID po IMM - 1 - 104 (TGI = 95%) IMM - 1 - 104 (TGI = 91%) Binimetinib + Encorafenib (10 mg/kg BID + 60 mg/kg QD p.o.) (N=12, per group) Encorafenib (TGI = 41%) minus 1 TV limit Binimetinib (TGI = 79%) Bin + Enc (TGI = 62%) 0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 0 250 500 750 1000 1250 1500 1750 2000 2250 2500 Time (days) T u m o r v o l u m e ( M e d i a n ± Q u a r t i l e ; m m 3 ) **Data: TV (mm3) - 60 mpk QD:10 mpk BID - E:B MEDIAN Vehicle 0 mg/kg QD po : Vehicle 0 mg/kg BID po MEDIAN 60 mg/kg Encorafenib QD po : Vehicle 0 mg/kg BID po MEDIAN Vehicle 0 mg/kg QD po : 10 mg/kg Binimetinib BID po MEDIAN 60 mg/kg Encorafenib QD po : 10 mg/kg Binimetinib BID po 0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 0 250 500 750 1000 1250 1500 1750 2000 2250 2500 Time (days) T u m o r v o l u m e ( M e d i a n ± Q u a r t i l e ; m m 3 ) **Data: TV (mm3) - 60 mpk QD:10 mpk BID - E:B MEDIAN Vehicle 0 mg/kg QD po : Vehicle 0 mg/kg BID po MEDIAN 60 mg/kg Encorafenib QD po : Vehicle 0 mg/kg BID po MEDIAN Vehicle 0 mg/kg QD po : 10 mg/kg Binimetinib BID po MEDIAN 60 mg/kg Encorafenib QD po : 10 mg/kg Binimetinib BID po 35
Head - to - Head Comparison of IMM - 1 - 104 versus Binimetinib +/ - Encorafenib in BRAF - V600E Melanoma Tumor Model A375 (BRAF V600E ) Melanoma Xenograft Tumor Model in Athymic Nude Mice Tumor Growth Inhibition (TGI) % = [1 – ( T i – T 0 )/(C i – C 0 )]x100%; Expanded TGI formula vs. previous 1 - [T/C]x100% method Human Dose Equivalent (HDE) binimetinib 1 - 3 mg/kg BID IMM - 1 - 104 as compared to binimetinib monotherapy demonstrated greater tumor growth inhibition (TGI) Binimetinib and encorafenib were commercially purchased IMM - 1 - 104 (100 & 150 mg/kg BID p.o.) (N=12, per group) Binimetinib + Encorafenib (10 mg/kg BID + 60 mg/kg QD p.o.) (N=12, per group) IMM - 1 - 104 (TGI = 80%) (TGI = 96%) Encorafenib (TGI = 99%) Binimetinib (TGI = 51%) Bin + Enc (TGI = 107%) Tumor Volume (Median ± quartile; mm 3 ) 0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 0 250 500 750 1000 1250 1500 1750 2000 2250 2500 2750 3000 3250 3500 Time (days) T u m o r v o l u m e ( M e d i a n ± Q u a r t i l e ; m m 3 ) **Data: TV (mm3) - 100 + 150 mpk - IMM-1-104 MEDIAN Vehicle 0 mg/kg BID po MEDIAN 150 mg/kg IMM-01-00104 BID po MEDIAN 100 mg/kg IMM-01-00104 BID po 0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 0 250 500 750 1000 1250 1500 1750 2000 2250 2500 Time (days) T u m o r v o l u m e ( M e d i a n ± Q u a r t i l e ; m m 3 ) **Data: TV (mm3) - 60 mpk QD:10 mpk BID - E:B MEDIAN Vehicle 0 mg/kg QD po : Vehicle 0 mg/kg BID po MEDIAN 60 mg/kg Encorafenib QD po : Vehicle 0 mg/kg BID po MEDIAN Vehicle 0 mg/kg QD po : 10 mg/kg Binimetinib BID po MEDIAN 60 mg/kg Encorafenib QD po : 10 mg/kg Binimetinib BID po 0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 0 250 500 750 1000 1250 1500 1750 2000 2250 2500 2750 3000 3250 3500 Time (days) T u m o r v o l u m e ( M e d i a n ± Q u a r t i l e ; m m 3 ) **Data: TV (mm3) - 100 + 150 mpk - IMM-1-104 MEDIAN Vehicle 0 mg/kg BID po MEDIAN 150 mg/kg IMM-01-00104 BID po MEDIAN 100 mg/kg IMM-01-00104 BID po Tumor Volume (Median ± quartile; mm 3 ) 36
Conclusions (NRAS mutant Melanoma) In the phase 3 NEMO study published in Lancet (c. 2017), binimetinib failed to substantially improve overall survival vs. dacarbazine (11.0 vs. 10.1 months) in NRAS mutant melanoma patients and led to a ~50% increase in serious adverse events (34% vs. 22%). The most common NRAS mutation in the NEMO study was Q61R. We further compared binimetinib vs. IMM - 1 - 104 in vivo using SK - MEL - 2 (NRAS - Q61R). Collectively, our data suggest that binimetinib may not effectively control MAPK pathway reactivation in RAS mutant tumors. In contrast, the deep cyclic inhibition combined with a dual - MEK mechanism of action of IMM - 1 - 104 may offer a unique therapeutic advantage over first generation MEK inhibitors in RAS mutant tumors. 37
38 RAS Mutation Profiles Within Select Tumor Indications • Based on given tumor type of patients with RAS - mutated tumors in the AACR GENIE database, v13.0 • Each RAS paralogue shown as percent overall RAS mutant tumors within each indication • Presented at 2023 AACR: Targeting RAS. Kolitz, et al. (Philadelphia, PA) 4 5 4 . 4 / 4 + * 5 * ' * ' 15$6RWKHU 4 . +5$6RWKHU * & * ' * $ * 5 * 6 * 9 4 * .5$62WKHU 0HODQRPD *(1( 15$6 +5$6 .5$6 * & * $ * 6 4 * .5$62WKHU 3DQFUHDWLF$GHQRFDUFLQRPD *(1( 15$6 +5$6 .5$6 * $ * 5 * 6 4 * .5$62WKHU /XQJ$GHQRFDUFLQRPD *(1( 15$6 +5$6 .5$6 Pancreatic Cancer NRAS = 0.34% HRAS = 0.06% KRAS = 99.60% NRAS = 2.67% HRAS = 0.31% KRAS = 97.02% Lung Cancer Melanoma Colorectal Cancer NRAS = 89.14% HRAS = 5.29% KRAS = 5.57% NRAS = 8.25% HRAS = 0.24% KRAS = 91.51% 4 . * ' 4 5 15$6RWKHU * & * $ * 5 * 6 4 * .5$62WKHU &RORUHFWDO$GHQRFDUFLQRPD *(1( 15$6 +5$6 .5$6
KRAS Mutant Pancreatic (PAAD): Translational Opportunity GENIE cohort v13.0 - public The AACR Project GENIE Consortium. AACR Project GENIE: Powering Precision Medicine Through An International Consortium, Cance r D iscov. 2017 Aug;7(8):818 - 831 ↑ Resistance Mixed Sensitive Have Altered KRAS: Biomarker Positive Biomarker Sensitive Profile (80.2% overall) Biomarker Resistant Profile (0.6% overall) † Further Biomarker Stratification Not Required † PANCREATIC Patients Patient mapping with 3D - TGA Translational Step : Assess sensitivity of a panel of cell lines in the 3D - TGA; determine key mutations present in each Bioinformatics Step : How many patients does each cell line represent, based on key mutations present in each 39
NRAS Mutant Melanoma: Translational Opportunity ↑ Resistance Mixed Sensitive Have Altered NRAS: Biomarker Positive Biomarker Sensitive Profile (19% overall) Biomarker Resistant Profile (0.8% overall) † Further Biomarker Stratification Not Required † MELANOMA Patients GENIE cohort v13.0 - public The AACR Project GENIE Consortium. AACR Project GENIE: Powering Precision Medicine Through An International Consortium, Cance r D iscov. 2017 Aug;7(8):818 - 831 Patient mapping with 3D - TGA Translational Step : Assess sensitivity of a panel of cell lines in the 3D - TGA; determine key mutations present in each Bioinformatics Step : How many patients does each cell line represent, based on key mutations present in each 40
KRAS Mutant NSCLC (Adeno): Translational Opportunity Have Altered KRAS: Biomarker Positive Biomarker Sensitive Profile (21.5% overall) Biomarker Resistant Profile (Refine Subsets) NSCLC - Ad Patients † ↑ Resistance (Further Refine Subsets) Sensitive † Consider Further Biomarker Stratification GENIE cohort v13.0 - public The AACR Project GENIE Consortium. AACR Project GENIE: Powering Precision Medicine Through An International Consortium, Cance r D iscov. 2017 Aug;7(8):818 - 831 Patient mapping with 3D - TGA Translational Step : Assess sensitivity of a panel of cell lines in the 3D - TGA; determine key mutations present in each Bioinformatics Step : How many patients does each cell line represent, based on key mutations present in each 41
KRAS Mutant CRC: Translational Opportunity Have Altered KRAS: Biomarker Positive Biomarker Sensitive Profile (9.3% overall) Biomarker Resistant Profile (Refine Subsets) CRC Patients † ↑ Resistance (Further Refine Subsets) Sensitive † Further Refine Biomarker Stratification GENIE cohort v13.0 - public The AACR Project GENIE Consortium. AACR Project GENIE: Powering Precision Medicine Through An International Consortium, Cance r D iscov. 2017 Aug;7(8):818 - 831 Patient mapping with 3D - TGA Translational Step : Assess sensitivity of a panel of cell lines in the 3D - TGA; determine key mutations present in each Bioinformatics Step : How many patients does each cell line represent, based on key mutations present in each 42
Translating IMM - 1 - 104’s Universal - RAS Potential (AACR GENIE ® ) 43 Nair, et al. 2023, AACR: National Meeting, Orlando, FL MAPK + = GENIE patients per indication with activation mutation in KRAS, NRAS, HRAS, BRAF (class I or II), based on 3D - TGA PGx Modeling 0$3.0XWDWHG 1 0$3.:7 1 3$$' 1XPEHURI*(1( 3DWLHQWV RI*(1( 3DWLHQWV PANCREATIC Lower Response Potential | Higher Response Potential Biomarker vs. Population Mutations PAAD For 122 3 D - TGA cell lines where in - house WES data were also collected, the upper plateau - to - 1 uM difference was used to delineate responder from non - responder, and thus train a logistic regression model with 10 - fold cross validation . There were 28 features used, one comprised of a consolidated MAPK mutations status (mutations in K/H/NRAS, GNAQ/ 11 , and BRAF class I/II), and 27 other genes representing key pathways . With an AUC of 0 . 84 on the training cohort and 0 . 72 on test cohort, the model was then applied to GENIE cohorts (above) where all features were included on the testing panel . For each indication of interest, a kernel density plot of the probability of predicted response for the entire cohort (projected onto the negative y - axis), and the MAPK(+) subset (positive y - axis) shows enrichment for higher probability of response with restriction to MAPK alteration status .
Translating IMM - 1 - 104’s Universal - RAS Potential (AACR GENIE ® ) 44 Nair, et al. 2023, AACR: National Meeting, Orlando, FL MAPK + = GENIE patients per indication with activation mutation in KRAS, NRAS, HRAS, BRAF (class I or II), based on 3D - TGA PGx Modeling For 122 3 D - TGA cell lines where in - house WES data were also collected, the upper plateau - to - 1 uM difference was used to delineate responder from non - responder, and thus train a logistic regression model with 10 - fold cross validation . There were 28 features used, one comprised of a consolidated MAPK mutations status (mutations in K/H/NRAS, GNAQ/ 11 , and BRAF class I/II), and 27 other genes representing key pathways . With an AUC of 0 . 84 on the training cohort and 0 . 72 on test cohort, the model was then applied to GENIE cohorts (above) where all features were included on the testing panel . For each indication of interest, a kernel density plot of the probability of predicted response for the entire cohort (projected onto the negative y - axis), and the MAPK(+) subset (positive y - axis) shows enrichment for higher probability of response with restriction to MAPK alteration status . 0$3.0XWDWHG 1 0$3.:7 1 6.&00(/ 1XPEHURI*(1( 3DWLHQWV RI*(1( 3DWLHQWV MELANOMA Lower Response Potential | Higher Response Potential Biomarker vs. Population Mutations SKCM MEL
Translating IMM - 1 - 104’s Universal - RAS Potential (AACR GENIE ® ) 45 Nair, et al. 2023, AACR: National Meeting, Orlando, FL MAPK + = GENIE patients per indication with activation mutation in KRAS, NRAS, HRAS, BRAF (class I or II), based on 3D - TGA PGx Modeling For 122 3 D - TGA cell lines where in - house WES data were also collected, the upper plateau - to - 1 uM difference was used to delineate responder from non - responder, and thus train a logistic regression model with 10 - fold cross validation . There were 28 features used, one comprised of a consolidated MAPK mutations status (mutations in K/H/NRAS, GNAQ/ 11 , and BRAF class I/II), and 27 other genes representing key pathways . With an AUC of 0 . 84 on the training cohort and 0 . 72 on test cohort, the model was then applied to GENIE cohorts (above) where all features were included on the testing panel . For each indication of interest, a kernel density plot of the probability of predicted response for the entire cohort (projected onto the negative y - axis), and the MAPK(+) subset (positive y - axis) shows enrichment for higher probability of response with restriction to MAPK alteration status . ȫ ȫ ȫ 00 3DWLHQW3URMHFWLRQIRU5HVSRQVHLQ*(1(&RKRUWV /8$' 0$3.0XWDWHG 1 0$3.:7 1 /8$' 1XPEHURI*(1( 3DWLHQWV RI*(1( 3DWLHQWV LUNG Lower Response Potential | Higher Response Potential All Patients | Biomarker + Biomarker vs. Population Mutations LUAD
Translating IMM - 1 - 104’s Universal - RAS Potential (AACR GENIE ® ) 46 Nair, et al. 2023, AACR: National Meeting, Orlando, FL MAPK + = GENIE patients per indication with activation mutation in KRAS, NRAS, HRAS, BRAF (class I or II), based on 3D - TGA PGx Modeling For 122 3 D - TGA cell lines where in - house WES data were also collected, the upper plateau - to - 1 uM difference was used to delineate responder from non - responder, and thus train a logistic regression model with 10 - fold cross validation . There were 28 features used, one comprised of a consolidated MAPK mutations status (mutations in K/H/NRAS, GNAQ/ 11 , and BRAF class I/II), and 27 other genes representing key pathways . With an AUC of 0 . 84 on the training cohort and 0 . 72 on test cohort, the model was then applied to GENIE cohorts (above) where all features were included on the testing panel . For each indication of interest, a kernel density plot of the probability of predicted response for the entire cohort (projected onto the negative y - axis), and the MAPK(+) subset (positive y - axis) shows enrichment for higher probability of response with restriction to MAPK alteration status . ȫ ȫ 00 3DWLHQW3URMHFWLRQIRU5HVSRQVHLQ*(1(&RKRUWV &2$'5($'&2$'5($' 0$3.0XWDWHG 1 0$3.:7 1 &2$'5($'&2$'5($' 1XPEHURI*(1( 3DWLHQWV RI*(1( 3DWLHQWV COLORECTAL Lower Response Potential | Higher Response Potential Biomarker vs. Population Mutations COAD READ COADREAD All Patients | Biomarker +
Translating IMM - 1 - 104’s Universal - RAS Potential (AACR GENIE ® ) 47 Nair, et al. 2023, AACR: National Meeting, Orlando, FL MAPK + = GENIE patients per indication with activation mutation in KRAS, NRAS, HRAS, BRAF (class I or II), based on 3D - TGA PGx Modeling For 122 3 D - TGA cell lines where in - house WES data were also collected, the upper plateau - to - 1 uM difference was used to delineate responder from non - responder, and thus train a logistic regression model with 10 - fold cross validation . There were 28 features used, one comprised of a consolidated MAPK mutations status (mutations in K/H/NRAS, GNAQ/ 11 , and BRAF class I/II), and 27 other genes representing key pathways . With an AUC of 0 . 84 on the training cohort and 0 . 72 on test cohort, the model was then applied to GENIE cohorts (above) where all features were included on the testing panel . For each indication of interest, a kernel density plot of the probability of predicted response for the entire cohort (projected onto the negative y - axis), and the MAPK(+) subset (positive y - axis) shows enrichment for higher probability of response with restriction to MAPK alteration status .
Exhibit 99.2
Immuneering Announces Positive Initial Phase 1 Pharmacokinetic, Pharmacodynamic and Safety Data for IMM-1-104 Universal-RAS Program; Accelerates Study Timeline
| ● | Data presented at AACR Annual Meeting support IMM-1-104's potential to address a broad population of patients with RAS mutant tumors |
| ● | IMM-1-104 well tolerated with no dose limiting toxicities (DLTs) or serious adverse events (SAEs) observed |
| ● | First demonstration of novel deep cyclic inhibition mechanism in humans, with IMM-1-104 achieving significant levels of PK Cmax and a half-life of approximately two hours as predicted |
| ● | Pharmacodynamic data support potential to evaluate preliminary efficacy sooner than expected |
| ● | Study timeline accelerated: recommended Phase 2 dose (RP2D) now expected in early 2024 |
| ● | Investor call to be held today at 9.00 a.m. ET |
CAMBRIDGE, Mass., April 18, 2023 — Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company developing medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy, announced positive initial pharmacokinetic (PK), pharmacodynamic (PD) and safety data from the Phase 1 trial of IMM-1-104 (NCT05585320), which are being shared today in a poster presentation titled “Humanized 3D tumor models that are mutationally aligned with AACR GENIE patients predict IMM-1-104 activity in RAS-addicted tumors” (abstract #4265) at the American Association for Cancer Research (AACR) annual meeting.
“We are very pleased to share initial PK, PD and safety data from our Phase 1 trial of IMM-1-104 in patients with advanced RAS mutant solid tumors, ahead of schedule,” said Ben Zeskind, Ph.D., MBA, Co-founder, and Chief Executive Officer of Immuneering. “We believe these data from the first patients dosed in our study demonstrate the PK, PD and safety profile necessary for deep cyclic inhibition – the proprietary and novel mechanism through which our therapies are designed to selectively impact cancer cells to a greater extent than healthy cells, regardless of the specific RAS mutation driving the tumor. The data show that we were able to reach significant levels of PK Cmax with the aim of breaking tumor addiction to the MAPK pathway, then rapidly clearing out drug with IMM-1-104’s short half-life. These results position us to accelerate the dose escalation portion of our study, reaching potentially therapeutic levels of IMM-1-104 earlier than previously planned.”
“These initial PK and PD Phase 1 data with IMM-1-104 mark a major milestone for Immuneering, and for patients affected by RAS mutant tumors. It is the first time IMM-1-104 has shown the profile we believe is necessary for deep cyclic inhibition in humans. Prior therapies have often suffered from steep increases in drug half-life in humans when compared to preclinical models. In contrast, initial clinical results for IMM-1-104 are in line with our preclinical modeling, which we believe helps to de-risk an important element of our universal-RAS program,” said Brett Hall, Ph.D., Chief Scientific Officer of Immuneering. “With today’s results showing an approximate two-hour half-life coupled with reaching target Cmax values faster than expected plus encouraging pharmacodynamic, safety and tolerability results observed, we are accelerating the remaining dose-escalation portion of our trial. We now have an opportunity to assess potential preliminary efficacy earlier than anticipated.”
“We are highly encouraged by the initial safety and tolerability data generated to date. IMM-1-104 has been well tolerated with no DLTs or SAEs observed,” said Scott Barrett, M.D., Chief Medical Officer of Immuneering. “We are grateful to the patients participating in our trial, and to the investigators. Investigator enthusiasm remains high, which combined with our study’s broad inclusion criteria, gives us confidence in our ability to keep enrolling patients in an expeditious manner.”
The Phase 1/2a clinical trial is an open-label study designed to evaluate the safety, tolerability, PK and preliminary efficacy of IMM-1-104 in patients with advanced RAS mutant solid tumors. The Phase 1 portion of the study, which is being conducted at five clinical sites in the United States, is evaluating IMM-1-104 following a Bayesian mTPI-2 escalation design, which includes a dose escalation phase and dose evaluation phase to establish an optimized RP2D candidate. Following selection of the RP2D candidate, the Company expects to conduct a Phase 2a dose expansion phase to assess the safety and efficacy of IMM-1-104 at the RP2D in RAS mutated pancreatic, melanoma, lung and colorectal cancers.
Highlights of the initial IMM-1-104 Phase 1 PK, PD and safety data presented at AACR include (as of data cut-off date of April 10, 2023, including patients with pancreatic and colon cancer):
| ● | Significant PK Cmax levels (plasma concentration of therapy in a specific area of the body) observed with IMM-1-104 of over 2,000 ng/mL (or approximately 1 uM drug free-fraction at 160 mg once daily oral dose) |
| ● | Greater than 90 percent PD inhibition of phosphorylated extracellular signal-regulated kinase (pERK) with IMM-1-104 compared to pretreatment baseline for patients at the third dose level (160 mg once daily oral) |
| ● | A median plasma half-life (t1/2) of 1.94 hours observed with IMM-1-104 across the first three dose levels evaluable (40 mg, 80 mg and 160 mg once daily oral), in patients with pancreatic and colorectal cancer with different RAS mutations, including KRAS-G12D, the most common mutation present in pancreatic cancer |
| ● | IMM-1-104 was well tolerated with no DLTs or SAEs observed and no drug-related adverse events beyond Grade 1 observed |
Based on the encouraging initial data presented today, Immuneering has updated guidance for the anticipated timing of announcing a RP2D for IMM-1-104 for its Phase 1/2a study. Management now expects to announce the RP2D in early 2024, versus prior guidance of mid-2024.
Other data presented at AACR:
In addition, IMM-1-104 was evaluated in humanized 3D preclinical tumor models displaying diverse mitogen-activated protein kinase (MAPK) pathway activation events. The MAPK pathway consists of a series of protein kinases such as RAS, RAF, MEK and ERK that are involved in many important cellular processes including cell proliferation, differentiation and survival. The antitumor activity of IMM-1-104 was evaluated in 132 tumor models spanning 12 distinct tumor types in a proprietary humanized 3D tumor growth assay (3D-TGA) conducted in Immuneering’s labs in San Diego. Based on drug-response sensitivity and resistance profiles, a biomarker signature for IMM-1-104 was developed to project potential therapeutic response in more than 100,000 cancer patients found in the AACR Project GENIE® database. Mutational landscapes of patients within GENIE helped identify preclinical models that represent patient profiles likely to be encountered in the clinic. These results were utilized in prioritizing indications for the planned Phase 2a clinical trial.
Updated Near-Term Milestone Expectations
IMM-1-104
| ● | Additional trial updates expected on a periodic basis. |
| ● | RP2D and additional safety data expected in early 2024. |
IMM-6-415
| ● | IND filing expected in the fourth quarter of 2023. |
Conference Call
Immuneering will host a conference call and live webcast at 9:00 a.m. ET / 6:00 a.m. PT on April 18, 2023, to discuss the results and provide a business update. Individuals interested in listening to the live conference call may do so by using the webcast link in the “Investors” section of the company’s website at www.immuneering.com. A webcast replay will be available in the investor relations section on the company’s website for 90 days following the completion of the call.
About IMM-1-104
IMM-1-104 aims to achieve universal-RAS activity that selectively impacts cancer cells to a greater extent than healthy cells, through deep cyclic inhibition of the MAPK pathway with once-daily dosing. IMM-1-104 is currently being evaluated in a Phase 1/2a study in patients with advanced solid tumors harboring RAS mutations (NCT05585320).
About Immuneering Corporation
Immuneering is a clinical-stage oncology company developing medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy. The company aims to achieve universal activity through deep cyclic inhibition of the MAPK pathway, impacting cancer cells while sparing healthy cells. Immuneering’s lead product candidate, IMM-1-104, is in a Phase 1/2a study in patients with advanced solid tumors harboring RAS mutations. The company’s development pipeline also includes IMM-6-415, a universal-MAPK program, as well as several early-stage programs. For more information, please visit www.immuneering.com.
Forward-Looking Statements
This press release includes certain disclosures that contain "forward-looking statements," including, without limitation, statements regarding Immuneering’s expectations regarding the treatment potential of IMM-1-104, the design, enrollment criteria and conduct of the Phase 1/2a clinical trial, the translation of preclinical data into human clinical data, the ability of initial clinical data to de-risk IMM-1-104 and be confirmed as the study progresses, including the safety, tolerability, pharmacokinetics, pharmacodynamics and potential efficacy of IMM-1-104; the potential advantages and effectiveness of the company’s clinical and preclinical candidates, the timing of additional trial updates, recommended phase 2 dose and additional safety data, the indications to be pursued by Immuneering in the Phase 2a portion of the study, the timing of submission of the IND for IMM-6-415, and Immuneering’s ability to advance its pipeline and further diversify its portfolio and make progress towards its longstanding goal of creating better medicines for cancer patients. Forward-looking statements are based on Immuneering’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, the risks inherent in oncology drug research and development, including target discovery, target validation, lead compound identification, lead compound optimization, preclinical studies, and clinical trials. These and other risks and uncertainties are described more fully in the section titled "Risk Factors" in Immuneering’s most recent Form 10-K filed with the U.S. Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Immuneering undertakes no duty to update such information except as required under applicable law.
Media Contact:
Gina Nugent
Nugent Communications
617-460-3579
gina@nugentcommunications.com
Investor Contacts:
Laurence Watts
Gilmartin Group
619-916-7620
laurence@gilmartinir.com
or
Kiki Patel, PharmD
Gilmartin Group
508-320-1110
kiki@gilmartinir.com